|
Patent landscape, scope, and claims summary: |
United States Patent 10,272,050 (Claims-Only) Landscape: What the Claims Cover, What They Don’t, and Where Design-Arounds and Risk Concentrate
Executive summary
US 10,272,050 is drafted around a non-crosslinked core-shell nanoparticle where a polymer shell undergoes temperature-dependent conformational changes that reversibly change nanoparticle size to enable biomolecule loading from an aqueous, solvent-free medium. The claim set is broad at the concept level (temperature-responsive, non-crosslinked polymer shell; biomolecule selectively encapsulated), and narrows through: (i) specified core chemistries (aliphatic polyesters including PLAs/PLG), (ii) specified shell chemistries (poloxamers of a defined general formula with specific PEO/PPO characteristics), (iii) specific biomolecules (EPO, insulin, hGH, IL-2, IL-10), and (iv) loading protocol windows (first and second temperatures). The non-crosslinked constraint and the solvent-free loading requirement are the two cleanest “claim-defining” levers for both freedom-to-operate (FTO) filtering and litigation posture.
However, a claims-only input is not enough to map the full patent estate, verify prosecution history, or determine which dependent claims drive enforceability against specific commercial products or processes. No bibliographic data, family members, continuations, claim construction history, or citation network is provided. The analysis below therefore focuses on: (1) claim mechanics and enforceable scope inferred from the literal language, (2) a critical “what must be true” checklist for infringement, (3) the most likely non-infringement/design-around pathways, and (4) a structured risk framework tied to typical US nanoparticle encapsulation landscapes.
1) What is the core claim scope of US 10,272,050 and how is infringement determined?
Short answer (claim essence)
US 10,272,050 claim 1 requires, in one composition, all of the following: a core nanoparticle with an outer polymer layer that is not crosslinked, the biomolecule is selectively encapsulated in that outer layer, and the polymer exhibits temperature-dependent conformational changes that change nanoparticle size by enough to permit encapsulation from aqueous medium substantially free of organic solvent. The composition must be prepared via a two-temperature process: expand at a first temperature to allow entry of the biomolecule, then contract at a second temperature to encapsulate.
Claim 1 elements broken into an infringement “truth table”
-
Nanoparticle architecture
- Must be a nanoparticle with:
- a core
- an outer layer comprising a polymer surrounding the core
Practical implication: A manufacturer can avoid by using a different architecture (eg, shell-free aggregates, or polymer-matrix systems where the “outer layer” does not surround a distinct core).
-
Encapsulation location
- Biomolecule must be “selectively encapsulated in the outer layer.”
- This is stricter than “entire particle contains biomolecule.” If a product has the biomolecule mostly in the core or in an internal matrix not constituting “outer layer,” infringement is weaker on the location limitation.
-
Temperature-responsive polymer behavior
- Polymer exhibits temperature-dependent conformational changes that:
- “change the size of the nanoparticle”
- by an amount sufficient to provide encapsulation from aqueous solvent-free conditions
The size-change limitation matters. A temperature-sensitive polymer that changes conformation without measurable size change could be argued non-infringing. In practice, defendants will attack whether any size change is sufficient to meet “amount sufficient to provide for encapsulation.”
-
Non-crosslinked shell constraint
- “Polymer surrounding the core is not crosslinked.”
This is a high-value design-around and enforcement pivot.
- It can exclude shells that are chemically crosslinked, photochemically crosslinked, or physically crosslinked in a way that results in a stable network consistent with “crosslinked” under ordinary meaning and claim construction.
-
Solvent environment during loading
- Encapsulation must be from an aqueous medium “substantially free of organic solvent.”
- This limitation targets conventional organic solvent nanoparticle formation/loading routes (eg, double-emulsion in organic phases, solvent evaporation requiring organic phases).
- It is not a total “zero solvent” standard in the claim language; it is “substantially free,” leaving room for interpretive fights on analytical residuals.
-
Process limitations are part of the composition claim
- Claim 1 includes that the composition is “prepared by a method comprising”:
- (a) preparing nanoparticle + polymer in aqueous solvent-free medium with biomolecule dissolved/suspended
- (b) subjecting to a first temperature where polymer expands to allow entry
- (c) subjecting to a second temperature where polymer contracts to encapsulate
In US practice, composition claims with method-preparation language are often enforced against end products if the infringing manufacturing method is effectively part of what makes the composition. But defendants may still litigate whether “prepared by” imposes an end-product condition or a product-by-process requirement.
Dependent claims define a narrower “second tier” scope
- Claim 2 quantifies “amount sufficient” for encapsulation as ~5% to ~500% (of what is not explicitly stated in your excerpt; typically the claim would define percent size change or expansion ratio).
- Claim 3/8 pin the core to aliphatic polyester polymers: PLA, PGA, PLG (and copolymers of lactic and glycolic acid).
- Claim 4-6 pin the outer polymer to poloxamer with formula parameters:
- a = 2 to 200
- b = 10 to 100
- poloxamer has PPO central chain MW 3000–5000 g/mol
- PEO content 60–80 wt%
- Claim 7/11 narrows biomolecules to EPO, insulin, hGH, IL-2, IL-10.
- Claim 9 gives temperature windows:
- first: 0°C to 20°C
- second: 20°C to 50°C
- Claim 10/11 adds administration method coverage using a “therapeutically effective amount” of claim 1 composition for specified biomolecules.
2) What aspects of the claims are most likely to be litigated: “not crosslinked,” “substantially free,” “size change,” and “selective encapsulation”?
A. “Polymer is not crosslinked”
This is the cleanest binary limitation. Likely litigation axes:
- Chemical crosslinks: covalent bonds introduced intentionally.
- Physical crosslinking: if the polymer forms a network via multivalent interactions; argument will turn on whether that is “crosslinked” in the claim sense.
- Stability after thermal cycling: a defendant may argue the system is reversibly responsive and does not become a crosslinked network.
Design-around signal: If a competitor uses physically gelled or chemically crosslinked poloxamer-like systems, they may avoid literal infringement but will also face performance tradeoffs.
B. “Aqueous medium substantially free of organic solvent”
Litigation typically targets:
- residual solvent levels at the time of loading
- whether solvent-containing intermediates qualify as “preparing” step (claim recites preparation steps)
- whether any unavoidable co-solvent for stability breaks the “substantially free” standard
Design-around signal: Using minimal co-solvents during loading can attempt to steer outside the “substantially free” boundary. The risk is interpretive: the plaintiff may show that de minimis organic solvent still falls within “substantially free.”
C. “Temperature-dependent conformational changes that change nanoparticle size”
“Size change” provides an objective hook. Expect:
- DLS/particle tracking data
- defining whether the “size change” is during a defined interval
- whether expansion and contraction are reversible and correlate with polymer conformation
Design-around signal: Use a temperature-responsive polymer that changes hydration/aggregation state without a measurable “size of nanoparticle” change. Or create a system where temperature triggers drug release but does not meet the size-change magnitude threshold.
D. “Selectively encapsulated in the outer layer”
This is a structural distribution argument:
- Where is the biomolecule located: outer layer vs core?
- Is there a measurable gradient?
- Are the outer polymer chains actually surrounding and trapping the biomolecule?
Design-around signal: Place biomolecule preferentially in the core or in a separate internal matrix. Even if the outer layer contains some biomolecule, defendants will aim to show it is not “selectively encapsulated in the outer layer” per the claim.
3) Which dependent claims most constrain the likely target products, and which ones expand the enforcement perimeter?
Narrowing constraints with high commercial relevance
- Core is PLA/PGA/PLG (Claims 3 and 8)
- Many nanoparticle carriers in drug delivery use PLA/PLG, so this is not exotic.
- Outer layer is specific poloxamer composition (Claims 4-6)
- This is a stronger constraint. Many temperature-responsive polymers are not poloxamers.
- Even within poloxamers, the MW/PEO wt% constraints narrow the set.
- Specific biomolecules (Claims 7 and 11)
- If a product targets a different biomolecule, the method claim (claim 10/11) may not apply, but composition claim 1 may still apply if the biomolecule is not among the listed set. Claim 1 is not limited to those biomolecules based on your excerpt.
- Temperature windows (Claim 9)
- If a process uses expansion and contraction outside the ranges, that can avoid claim 9 but may not avoid claim 1 depending on whether claim 1 requires those ranges or just “first” and “second” temperatures generically.
Expansion levers (broader than typical formulation-only patents)
- Claim 1 is not limited to poloxamer or PLA/PLG.
- Claim 1 is not limited to particular biomolecules in your excerpt.
- The method of preparation is embedded but could be interpreted broadly for end-product coverage.
Net effect: Claim 1 is the enforcement centerpiece. Dependent claims drive additional fallback positions and narrower design-around opportunities.
4) What patent estate questions matter most for US 10,272,050, and what can be concluded from claims alone?
What can be concluded
- The patent is almost certainly centered on temperature-responsive polymer encapsulation in an aqueous, low-organic environment, with a non-crosslinked shell.
- If the claims were originally broader and later narrowed (common in prosecution), the specific poloxamer and temperature windows likely represent negotiated boundaries over prior art.
What cannot be concluded from your input
- There is no citation list, priority data, family members, continuation chain, claim amendment history, or examiner statements provided. Without these, any statement about:
- whether related continuations exist,
- whether key claims were allowed over specific prior art,
- which jurisdictions besides the US are covered,
- whether there are active or expired related patents,
would be speculative.
Per the constraints, this analysis is limited to what the claim set supports.
5) What prior-art risk themes typically attack claims like these, and where would the validity battleground likely be?
Even without the cited art, the claim drafting suggests predictable validity vectors:
A. Temperature-responsive amphiphilic polymers in aqueous media
Poloxamers and related amphiphilic block copolymers have long histories of:
- micellization
- thermal gelation
- reversible conformational/hydration changes with temperature
A validity attack usually argues that “temperature-dependent conformational changes” and “aqueous solvent-free loading” are known.
What saves the claim is the combination with:
- non-crosslinked outer polymer
- encapsulation from an aqueous medium substantially free of organic solvent
- size change magnitude sufficient to enable encapsulation
- core-shell architecture with outer-layer-selective encapsulation
- two-temperature loading protocol (expand to load, contract to encapsulate)
B. PLA/PLG core biomolecule encapsulation
PLA and PLG nanoparticles are ubiquitous. Prior art often includes:
- drug loading into PLA/PLG cores
- multiple emulsion/solvent evaporation approaches
The claim’s key distinction would be the outer polymer’s temperature-responsive behavior and the “not crosslinked” shell, plus the aqueous solvent-free loading process.
C. Product-by-process and end-product definition
A defense may argue:
- even if the process steps existed, the end product is defined by structure not process
- or conversely that process limitations should not limit composition if they do not create a distinct product characteristic.
These become claim construction questions in litigation, not just novelty.
6) How strong is the patent for exclusivity if competitors use close substitutes?
Highest-likelihood knockouts (literal non-infringement)
- Crosslinked shell
- Any intentional crosslinking likely avoids claim 1.
- Non-poloxamer shell chemistry
- Avoids dependent claims 4-6, but not necessarily claim 1.
- Loading not from “substantially free” aqueous organic solvent
- If meaningful organic solvent is used in loading, avoid the “substantially free” limitation.
- No nanoparticle size change
- If temperature changes polymer conformation but does not change nanoparticle size sufficiently, avoid the size-change limitation.
Highest-likelihood partial-infringement scenarios
- A competitor may use similar architecture but:
- use a different temperature window (potentially outside claim 9),
- use different poloxamer parameters (outside claims 4-6),
- use a different biomolecule (outside claims 7/11),
while still potentially falling under claim 1 if the architecture, non-crosslinked polymer, and process features match.
7) What generic entry risks exist for the underlying biologics (EPO/insulin/hGH/IL-2/IL-10), given this is a formulation patent?
Short answer
This patent is not a “generic drug” patent on an active ingredient. Its risk is formulation-level exclusivity affecting competitors who would seek to market the same biologic with the same claimed delivery system.
Practical enforcement posture
- Biologics exclusivity (BLA/505(b)(1)) is distinct from formulation patent exclusivity (which this likely is).
- Generic/biosimilar entry risk is focused on:
- whether the proposed product uses the same temperature-responsive, non-crosslinked core-shell system
- whether it is prepared via the same two-temperature expand/contract loading workflow
- whether the outer layer is poloxamer within the dependent claim bounds (if the plaintiff relies on dependent claims)
Because claim 1 is broad on biomolecule identity, a competitor with a different protein could still face claim 1 if the same delivery system is used.
8) What is the best likely design-around strategy based on the claim language?
Design-around map (priority order)
- Crosslink the outer shell (avoid the “not crosslinked” limitation)
- Keep encapsulation from a medium that is not “substantially free of organic solvent” (use a co-solvent strategy during loading)
- Use a non-temperature-responsive shell for encapsulation (temperature may be used for release, not for size-based loading)
- Make the biomolecule load into the core or into a non-“outer layer” domain
- Ensure temperature cycling does not produce sufficient size change to meet the claim’s “amount sufficient” limitation (especially if it is tied to a percent threshold in claim 2)
- Use shell polymers other than poloxamers with the specified formula/MW/PEO fraction to avoid dependent claim fallbacks
9) How do the method claims expand or contract commercial risk?
Claim 10 and 11: method of delivering
- Claim 10 is administration of a composition of claim 1.
- Claim 11 limits the therapeutic biomolecule to the set in your excerpt (EPO, insulin, hGH, IL-2, IL-10).
Implication:
Even if a competitor makes a non-claim-1-compliant formulation, they avoid the method claims. Conversely, if a competitor makes a claim-1-compliant composition but uses a different biomolecule, they may avoid the method claims but still face composition claim 1 exposure (again, based on claim 1 not being biomolecule-limited).
10) Key Takeaways
- US 10,272,050 is built around a non-crosslinked temperature-responsive polymer shell that expands/contracts to change nanoparticle size and enables biomolecule encapsulation from aqueous solvent-free conditions.
- Claim 1 is the core: it captures the delivery system regardless of biomolecule identity and is not limited to poloxamer or PLA/PLG.
- The strongest defensible design-around handles are:
- crosslinked vs non-crosslinked shell
- solvent content during loading
- whether temperature cycling yields sufficient size change
- where the biomolecule resides (outer layer selectivity)
- Dependent claims 3 and 4-6 constrain core and shell chemistry. Dependent claims 7 and 11 constrain biomolecules only for the method claims and those dependent compositions.
- Based on the claim language alone, the most realistic competitive risk is from products using similar core-shell architecture, similar temperature-responsive poloxamer-like behavior, and similar two-step loading.
FAQs
-
What does “not crosslinked” likely exclude in nanoparticle shell systems?
Any chemically crosslinked polymer network in the outer layer is the cleanest exclusion; physically crosslinked systems will depend on claim construction.
-
Does “substantially free of organic solvent” allow trace residual solvent?
Yes in principle; the boundary will be litigated through residual-solvent analytics and expert testimony tied to the claim’s “substantially” standard.
-
If a product uses a temperature-responsive shell but does not measurably change particle size, does it avoid claim 1?
It has a strong non-infringement pathway because claim 1 requires size change by an amount sufficient for encapsulation.
-
Can competitors avoid dependent claims by using poloxamers outside the specified MW/PEO range while still infringing claim 1?
Yes; dependent constraints narrow enforceability only if the plaintiff relies on dependent claims. Claim 1 remains broader on polymer identity.
-
How do administration method claims relate to end-product composition liability?
If the composition violates claim 1, administration can violate claim 10/11 only when the administered biomolecule matches the claim’s listed set.
References
- US Patent 10,272,050. (Claims provided in user prompt).
More… ↓
⤷ Start Trial
|
